PARPi are effective only in a small subset of pancreatic cancers that harbor BRCA1/2 mutations, as the majority of cases remain resistant to PARPi due to proficient BRCA1 activity. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.